Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Innovac Inc. has 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This action is assigned to 1 distinct examiner and 1 distinct art unit, which simplifies the company's current prosecution landscape. The practitioner can focus their strategy on the specific feedback provided by this single examiner.
The busiest examiner is SALVOZA, M FRANCO G, who is responsible for the 1 pending office action. With only 1 distinct examiner and 1 distinct art unit involved, the practitioner's primary goal is to address the concerns of this one individual. This concentrated environment allows for a highly tailored response to the 1 pending office action, as there are no other examiners or art units to consider.
In the Biotechnology & Pharmaceuticals field, the success of this 1 pending office action is critical for the company's immediate patent goals. The practitioner should analyze the typical examination patterns of the 1 distinct art unit to better support their arguments. Since SALVOZA, M FRANCO G is the only examiner involved, the entire prosecution path for this action is defined by their specific scrutiny.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| SALVOZA, M FRANCO G | 1 | 68.2% | +30.6% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18711502 | NOVEL RECOMBINANT PORCINE CIRCOVIRUS TYPE 2 PROTEIN AND USE THEREOF | SALVOZA, M FRANCO G | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18711502 | NOVEL RECOMBINANT PORCINE CIRCOVIRUS TYPE 2 PROTEIN AND USE THEREOF | SALVOZA, M FRANCO G | — |
| Art Unit | Apps |
|---|---|
| 1672 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18711502 | NOVEL RECOMBINANT PORCINE CIRCOVIRUS TYPE 2 PROTEIN AND USE THEREOF | SALVOZA, M FRANCO G | 1672 | §101§102§112 | Non-Final OA | — | Pending | May 17, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialInnovac Inc. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
M Franco G Salvoza has the most, with 1 of Innovac Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
